Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on September 9, 2002

Circulation. 2002
Published online before print September 9, 2002, doi: 10.1161/01.CIR.0000034444.31846.F4
A more recent version of this article appeared on September 24, 2002
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
106/13/1618    most recent
01.CIR.0000034444.31846.F4v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ooi, H.
Right arrow Articles by Givertz, M. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ooi, H.
Right arrow Articles by Givertz, M. M.
Related Collections
Right arrow Congestive
Right arrow Pulmonary circulation and disease

Submitted on June 24, 2002
Revised on August 8, 2002
Accepted on August 8, 2002

Endothelin Mediates Increased Pulmonary Vascular Tone in Patients With Heart Failure. Demonstration by Direct Intrapulmonary Infusion of Sitaxsentan

Henry Ooi MB, MRCPI, Wilson S. Colucci MD*, and Michael M. Givertz MD

From the Cardiovascular Section, Department of Medicine and the Cardiomyopathy Program, Boston University School of Medicine, Boston, Mass. Dr Givertz is currently at the Cardiovascular Division, Brigham and Women's Hospital, Boston, Mass.

* To whom correspondence should be addressed. E-mail: wilson.colucci{at}bmc.org.

Background—In patients with chronic heart failure (HF), the pulmonary circulation is a major source of endothelin-1 (ET), and ET levels correlate with pulmonary vascular resistance (PVR). The role of ET in causing pulmonary vasoconstriction in HF is not known, however, in part because of the confounding effects of ET receptor antagonists on systemic hemodynamics.

Methods and Results—To directly test the hypothesis that ET causes pulmonary vasoconstriction in patients with HF, we infused the selective ETA receptor antagonist sitaxsentan at increasing rates (0.3125 to 10 mg/min) into a left lower-lobe segmental pulmonary artery in 8 patients with left ventricular (LV) systolic failure (LV ejection fraction, 24±4%) and 4 control subjects with normal LV function. Changes in local PVR distal to the infusion site were assessed by measuring the change in pulmonary blood flow velocity with a Doppler-tipped wire and the mean pulmonary artery pressure (MPAP). Total PVR at baseline was elevated in HF patients (177±23 dyne · s · cm-5) versus controls (89±21 dyne · s · cm-5; P<0.05). In patients with HF, sitaxsentan caused an infusion rate-dependent decrease in local PVR (P<0.05 versus baseline; P<0.05 versus controls). In contrast, sitaxsentan infusion had no effect on local PVR in controls. Heart rate, mean arterial pressure, cardiac index, and MPAP were not affected by sitaxsentan in either group.

Conclusion—Selective ETA receptor blockade caused local pulmonary vasodilation in patients with HF, but not in control subjects with normal LV function. These data indicate that ET contributes to the secondary pulmonary hypertension associated with HF.


Key words: endothelin • heart failure • hypertension, pulmonary




This article has been cited by other articles:


Home page
ChestHome page
V. Faoro, S. Boldingh, M. Moreels, S. Martinez, M. Lamotte, P. Unger, S. Brimioulle, S. Huez, and R. Naeije
Bosentan Decreases Pulmonary Vascular Resistance and Improves Exercise Capacity in Acute Hypoxia
Chest, May 1, 2009; 135(5): 1215 - 1222.
[Abstract] [Full Text] [PDF]


Home page
Exp PhysiolHome page
L. Ray, M. Mathieu, P. Jespers, I. Hadad, M. Mahmoudabady, A. Pensis, S. Motte, I. R. Peters, R. Naeije, and K. McEntee
Early increase in pulmonary vascular reactivity with overexpression of endothelin-1 and vascular endothelial growth factor in canine experimental heart failure
Exp Physiol, March 1, 2008; 93(3): 434 - 442.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
J. G.F. Cleland, A. P. Coletta, M. Lammiman, K. K. Witte, H. Loh, M. Nasir, and A. L. Clark
Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE
Eur J Heart Fail, October 1, 2005; 7(6): 1070 - 1075.
[Abstract] [Full Text] [PDF]